Amneal Pharmaceuticals, Inc.
News
(8)April 2026
AMRX Seeks Shareholder Approval for Kashiv Acquisition
# 🧾 What This Document Is This is a "DEFA14A" filing, which is a **Definitive Additional Material** for a proxy statement. In plain English, it's not the official voting document itself, but **supplementary material** Amneal is sending to shareholders ahead of a vote. 👉 **Why it exists:** Amneal
Amneal acquires Kashiv BioSciences in deal valued up to $775 million
# 📄 What This Document Is 📰 This document is an 8-K, or a Current Report, which means Amneal is filing an urgent update with the SEC to inform the public about a major, material event that happened on or around April 22, 2026. Since the filing centers entirely on a large deal, it provides the det
Amneal seeks Kashiv acquisition to target $100 billion biosimilar market
# 📜 What This Document Is 🧩 This filing is a Definitive Proxy Statement (DEFA14A), a legal document submitted to the U.S. Securities and Exchange Commission (SEC) that contains information for the company's annual meeting of stockholders. Because the filing is specifically "Soliciting Material un
Amneal Acquires Kashiv BioSciences, Reports Strong Q1 Results
# 🧾 What This Document Is This is a **DEFA14A** filing, which stands for "Definitive Additional Materials" related to a proxy statement. Think of it as an update or supplement to an earlier proxy announcement. In this case, Amneal is using it to formally file and explain materials it shared on soci
Amneal Details Strategic Acquisition of Kashiv BioSciences for Biosimilar Growth
# 🧾 What This Document Is This is a **DEFA14A filing**, which stands for "Definitive Additional Materials" related to a proxy statement. Think of it as an add-on or supplement to a main proxy document. In this case, Amneal is using it to share an internal factsheet about its proposed acquisition of
Amneal Seeks Shareholder Approval for $500M Kashiv Deal
# 📜 What This Document Is This is a **DEFA14A filing**, which stands for "Definitive Additional Material" related to a proxy statement. Think of it as an official update sent to shareholders and the public about a vote they need to take. 👉 **Why it's filed:** Amneal is using this form to share a
AMRX Acquires Kashiv BioSciences, Raises Full-Year Guidance
# 📄 What This Document Is This is a **DEFA14A**, a type of SEC filing called "Definitive Additional Materials." Think of it as an official press release or internal memo sent to shareholders and the public that's required to be filed with the SEC because it relates to a proxy vote. 👉 **In this ca
AMRX Acquires Kashiv BioSciences for $375M Cash and Stock
# 🧾 What This Document Is This SEC filing is an 8-K report from Amneal Pharmaceuticals (AMRX). It announces a major acquisition by attaching the legal agreements that define the deal. Think of it as a public disclosure that says, "We're buying a company, and here are the exact contracts that spell
Peers in Drug Manufacturers - Specialty & Generic
Takeda Pharmaceutical Company Limited
Zoetis Inc.
Haleon plc
Teva Pharmaceutical Industries Limited
United Therapeutics Corporation
Viatris Inc.
Regencell Bioscience Holdings Limited
Neurocrine Biosciences, Inc.
Elanco Animal Health Incorporated
Dr. Reddy's Laboratories Limited